Program
Timolol
Also written as “Timolol Maleate Gel”, “bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy)” and “timolol 0.5%”.
Its studies are mostly in Glaucoma, Open-Angle · Glaucoma · Hemangioma, Capillary, led by 9 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVie | 80 open or running | phase 4since Aug 13, 2008 | Aug 13, 2008 | none ahead |
| Merck | 30 open or running | phase 3since Apr 12, 2005 | Apr 12, 2005 | none ahead |
| Santen Pharmaceutical | 30 open or running | phase 3since Feb 28, 2011 | Apr 7, 2009 | none ahead |
| Viatris | 30 open or running | phase 3since Sep 8, 2005 | Sep 8, 2005 | none ahead |
| Auson Pharmaceuticals | 20 open or running | phase 3since Oct 29, 2024 | Oct 29, 2024 | none ahead |
| Credit Valley EyeCare | 10 open or running | phase 4since Feb 13, 2012 | Feb 13, 2012 | none ahead |
| Glaukos | 10 open or running | phase 4since Jun 1, 2009 | Jun 1, 2009 | none ahead |
| Laboratorios Poen | 10 open or running | phase 4since Mar 30, 2023 | Mar 30, 2023 | none ahead |
| vistakon-pharmaceuticals | 10 open or running | phase 4since Dec 5, 2008 | Dec 5, 2008 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 9 studies since Apr 12, 2005.
- Jun 1, 2009Glaukos's first study: phase 4 study in Eye DiseasesNew to GlaukosGlaukos · NCT00913029 · 192 enrolled · Armenia, Austria, France and more
- Feb 12, 2010No phase study in Glaucoma, Open-AngleAbbVie · NCT01068964 · 235 enrolled · China
- Oct 5, 2010Phase 1 study in Glaucoma, Open-AngleAbbVie · NCT01215786 · 50 enrolled · United States
- Oct 7, 2010Phase 3 study in Glaucoma, Open-AngleAbbVie · NCT01217606 · 185 enrolled · Brazil
- Oct 26, 2010No phase study in GlaucomaAbbVie · NCT01229462 · 238 enrolled · China
- Nov 12, 2010Phase 3 study in Glaucoma, Open-AngleAbbVie · NCT01241240 · 192 enrolled · Colombia, Mexico
- Feb 28, 2011Phase 3 study in Ocular HypertensionSanten Pharmaceutical · NCT01306461 · 401 enrolled · Hungary
- Sep 12, 2011Phase 1 study in Healthy VolunteersSanten Pharmaceutical · NCT01434888 · 15 enrolled · Finland
- Feb 13, 2012Credit Valley EyeCare's first study: phase 4 study in GlaucomaNew to Credit Valley EyeCareCredit Valley EyeCare · NCT01535768 · 150 enrolled · Canada
- Jun 17, 2013Phase 4 study in GlaucomaAbbVie · NCT01881126 · 93 enrolled · Canada
- Mar 25, 2014Phase 4 study in GlaucomaAbbVie · NCT02097719 · 100 enrolled · United States
- Mar 30, 2023Laboratorios Poen's first study: phase 4 study in Glaucoma, Open-AngleNew to Laboratorios PoenLaboratorios Poen · NCT05857267 · 84 enrolled · Argentina
- Oct 29, 2024Auson Pharmaceuticals's first study: phase 3 study in Hemangioma, CapillaryNew to Auson PharmaceuticalsAuson Pharmaceuticals · NCT06677853 · 168 enrolled · China
- Jan 23, 2025Phase 1 study in Healthy SubjectsAuson Pharmaceuticals · NCT06824948 · 28 enrolled · China
TargetBeta
“Beta-1 adrenergic receptor antagonist; Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Epinephrinerule | nasus-pharma | phase 4 | 17 |
Studies
All 23 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06824948Healthy Subjects · China | 1 | Completed | Auson Pharmaceuticals | Dec 12, 2018 | 28 |
| NCT06677853Hemangioma, Capillary · China | 3 | Completed | Auson Pharmaceuticals | Jun 21, 2022 | 168 |
| NCT05857267Glaucoma, Open-Angle · Argentina | 4 | Completed | Laboratorios Poen | Nov 4, 2024 | 84 |
| NCT02097719Glaucoma · United States | 4 | Completed | AbbVie | Dec 2014 | 100 |
| NCT01881126Glaucoma · Canada | 4 | Completed | AbbVie | Oct 2014 | 93 |
| NCT01535768Glaucoma · Canada | 4 | UNKNOWN | Credit Valley EyeCare | Jun 2018 | 150 |
| NCT01434888Healthy Volunteers · Finland | 1 | Completed | Santen Pharmaceutical | Dec 2011 | 15 |
| NCT01306461Ocular Hypertension · Hungary | 3 | Completed | Santen Pharmaceutical | Apr 2012 | 401 |
| NCT01241240Glaucoma, Open-Angle · Colombia, Mexico | 3 | Completed | AbbVie | Sep 2013 | 192 |
| NCT01229462Glaucoma · China | – | Completed | AbbVie | Sep 2011 | 238 |
| NCT01217606Glaucoma, Open-Angle · Brazil | 3 | Completed | AbbVie | Sep 2014 | 185 |
| NCT01215786Glaucoma, Open-Angle · United States | 1 | Completed | AbbVie | Dec 2010 | 50 |
| NCT01068964Glaucoma, Open-Angle · China | – | Completed | AbbVie | Sep 1, 2010 | 235 |
| NCT00913029Eye Diseases · Armenia, Austria, France and more | 4 | Completed | Glaukos | Sep 2012 | 192 |
| NCT00879099Healthy · Finland | 1 | Completed | Santen Pharmaceutical | Jan 2010 | 12 |
| NCT00856622Ocular Hypertension · Germany | 3 | Completed | Viatris | Jun 1999 | 436 |
| NCT00832377Glaucoma | 2 | Completed | Merck | Mar 12, 2010 | 37 |
| NCT00804648Glaucoma, Open-Angle · United States | 4 | Completed | vistakon-pharmaceuticals | Dec 2008 | 30 |
| NCT00735449Glaucoma · United States, Canada | 4 | Completed | AbbVie | Dec 2009 | 204 |
| NCT00546286Glaucoma | 3 | Completed | Merck | Aug 23, 2007 | 170 |
| NCT00277498Glaucoma, Open-Angle · United States | 3 | Completed | Viatris | 528 | |
| NCT00159653Glaucoma, Open-Angle · United States, Canada | 3 | Completed | Viatris | Jun 2007 | 500 |
| NCT00108017Glaucoma | 3 | Completed | Merck | Jul 2006 | 330 |
How it is read
Names in the registry
- “Timolol Maleate Gel”, 4 entries
- “Timolol”, 3 entries
- “bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy)”, 2 entries
- “timolol 0.5%”, 2 entries
- “timolol maleate”, 2 entries
Conditions, from the studies’ own filings
- Glaucoma, Open-Angle, 14 studies
- Glaucoma, 9 studies
- Hemangioma, Capillary, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.